These Pills Could Be Next U.S. Drug Epidemic, Public Health Officials Say

Alprazolam, often referred to by the brand name Xanax, is among the most sold drugs in a class of widely prescribed anti-anxiety medications known as benzodiazepines.

Alprazolam, often referred to by the brand name Xanax, is among the most sold drugs in a class of widely prescribed anti-anxiety medications known as benzodiazepines. Shutterstock

 

Connecting state and local government leaders

Some states are restricting prescriptions for anti-anxiety medications known as benzodiazepines.

This article was originally published by Stateline, an initiative of The Pew Charitable Trusts, and was written by Christine Vestal.

The growing use of anti-anxiety pills reminds some doctors of the early days of the opioid crisis.

Considered relatively safe and non-addictive by the general public and many doctors, Xanax, Valium, Ativan and Klonopin have been prescribed to millions of Americans for decades to calm jittery nerves and promote a good night’s sleep.

But the number of people taking the sedatives and the average length of time they’re taking them have shot up since the 1990s, when doctors also started liberally prescribing opioid painkillers.

As a result, some state and federal officials are now warning that excessive prescribing of a class of drugs known as benzodiazepines or “benzos” is putting more people at risk of dependence on the pills and is exacerbating the fatal overdose toll of painkillers and heroin. Some local governments are beginning to restrict benzo prescriptions.

When taken in combination with painkillers or illicit narcotics, benzodiazepines can increase the likelihood of a fatal overdose as much as tenfold, according to the National Institute on Drug Abuse. On their own, the medications can cause debilitating withdrawal symptoms that last for months or years.

Public health officials also warn that people who abruptly stop taking benzodiazepines risk seizures or even death.

With heightened public awareness of the nation’s opioid epidemic, some state and local officials are insisting that these anti-anxiety medications start sharing some of the scrutiny.

“We have this whole infrastructure set up now to prevent overprescribing of opioids and address the need for addiction treatment,” said Dr. Anna Lembke, a researcher and addiction specialist at Stanford University. “We need to start making benzos part of that.”

“What we’re seeing is just like what happened with opioids in the 1990s,” she said. “It really does begin with overprescribing. Liberal therapeutic use of drugs in a medical setting tends to normalize their use. People start to think they’re safe and, because they make them feel good, it doesn’t matter where they get them or how many they use.”

The number of adults filling a benzodiazepine prescription increased by two-thirds between 1996 and 2013, from 8 million to nearly 14 million, according to a review of market data by Lembke and others in the New England Journal of Medicine. Despite the known dangers of co-prescribing painkillers and anti-anxiety medications, the rate of combined prescriptions nearly doubled between 2001 and 2013.

Since then, prescriptions for benzodiazepines may have leveled off or declined slightly, according to recent data from a market research firm that tracks prescription drug sales, the IQVIA Institute for Human Data Science. At the same time, opioid prescribing has dropped by more than a fifth.

Still, Lembke said, the level of prescribing is much higher than it was in the mid-1990s and benzo dependence appears to be rising based on her own clinical observations.

First marketed in the early 1960s, benzodiazepines have been cyclically abused throughout their history. What’s notable now, Lembke said, is that overuse of benzos is coinciding with overuse of opioids.

But a newly formed group of researchers and pharmacologists, the International Task Force on Benzodiazepines, wrote in an editorial that recent negative publicity has made it difficult for many doctors around the world to prescribe medications they consider essential.

Some scientific articles “achieved a common goal that negative propaganda frequently reaches: they aroused suspicion of benzodiazepines and suggested difficulties in using them, while overlooking their benefits,” the pharmacologists said. (Three of the 17 co-authors reported having consulted for or received support from drug companies.)

Psychiatrists, including Lembke, agree that relatively inexpensive benzodiazepines can be effective at relieving acute cases of anxiety and sleeplessness.

Physicians agree that benzos should not be used long term to solve psychiatric problems. Research indicates that use of the drugs for more than a few weeks can cause tolerance, including withdrawal symptoms between doses, and physical and psychological dependence.

To raise awareness of benzodiazepines’ dangers, Hawaii, Pennsylvania and New York City have issued prescribing guidelines that limit the duration of Xanax, Valium and other benzo prescriptions, similar to many state guidelines for opioids.

In addition, the Massachusetts Legislature this month passed a wide-ranging opioid bill that included benzodiazepines as a class of restricted drugs.

Nationwide, most states require doctors and pharmacists to track opioid prescribing through online databases that monitor patients who receive them and doctors who prescribe them. Benzodiazepines are not included in half of the states, according to an analysis of state laws by The Pew Charitable Trusts, which also supports Stateline.

Mounting Dangers

As prescriptions for benzodiazepines have grown since the late 1990s, so have deaths, according to a study at Montefiore Medical Center in New York. The National Institute on Drug Abuse reports that overdose deaths involving benzodiazepines quadrupled from 2002 to 2015.

New highly potent forms of benzodiazepines that are illicitly traded are also causing overdose deaths, addiction doctors say. Adding to the dangers, the Drug Enforcement Administration has reported that the deadly synthetic drug fentanyl has been found in counterfeit forms of Xanax.

Xanax and Valium were involved in more than 30 percent of opioid overdose deaths between 2010 and 2014, far more than cocaine and methamphetamines, according to the Centers for Disease Control and Prevention. In some parts of the country, the prevalence of Xanax in drug overdose autopsy reports was even higher.

Xanax for the past several years has been found in more overdose autopsies in Kentucky than any specific opioid, according to Dr. Kelly Clark, president of the American Society of Addiction Medicine and an addiction doctor who lives in the state. “In fact, community mental health centers in Louisville stopped prescribing Xanax because it is such a common drug of abuse and so dangerous in combination with alcohol and opioids,” she said in an interview with Stateline.

Better Information

Researchers and patient advocates argue more needs to be done to educate medical students and inform doctors and patients about the drugs’ dangers.

Dr. Christy Huff, who is in recovery from dependence on Xanax, co-directs the Utah-based Benzodiazepine Information Coalition. The nonprofit advocates for stronger warnings for patients who take Xanax and other benzos, as well as better education for prescribing physicians.

“Our population of patients is experiencing extremely difficult withdrawals, and they have neurological injuries because of unsafe prescribing,” Huff said. “Doctors need to be informed that the medications should be prescribed for no more than two to four weeks. They were always meant to be short term.”

In 2016, the Food and Drug Administration issued a warning about the dangers of combining opioids and benzodiazepines. That prompted many doctors to force patients to choose one drug over the other without warning them about the potential symptoms of withdrawal such as seizures or even death, Huff said.

“Patients who are on the medications should be given the choice of how and when they are tapered off,” she said. “Too many doctors are taking people off their prescriptions too rapidly.”

The benzo task force wrote in its editorial that it was developing research that it hoped would support preserving the drugs as a valuable part of the medical arsenal.

X
This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We also share information about your use of our site with our social media, advertising and analytics partners. Learn More / Do Not Sell My Personal Information
Accept Cookies
X
Cookie Preferences Cookie List

Do Not Sell My Personal Information

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link.

Allow All Cookies

Manage Consent Preferences

Strictly Necessary Cookies - Always Active

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data, Targeting & Social Media Cookies

Under the California Consumer Privacy Act, you have the right to opt-out of the sale of your personal information to third parties. These cookies collect information for analytics and to personalize your experience with targeted ads. You may exercise your right to opt out of the sale of personal information by using this toggle switch. If you opt out we will not be able to offer you personalised ads and will not hand over your personal information to any third parties. Additionally, you may contact our legal department for further clarification about your rights as a California consumer by using this Exercise My Rights link

If you have enabled privacy controls on your browser (such as a plugin), we have to take that as a valid request to opt-out. Therefore we would not be able to track your activity through the web. This may affect our ability to personalize ads according to your preferences.

Targeting cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Social media cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

If you want to opt out of all of our lead reports and lists, please submit a privacy request at our Do Not Sell page.

Save Settings
Cookie Preferences Cookie List

Cookie List

A cookie is a small piece of data (text file) that a website – when visited by a user – asks your browser to store on your device in order to remember information about you, such as your language preference or login information. Those cookies are set by us and called first-party cookies. We also use third-party cookies – which are cookies from a domain different than the domain of the website you are visiting – for our advertising and marketing efforts. More specifically, we use cookies and other tracking technologies for the following purposes:

Strictly Necessary Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Functional Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Performance Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Social Media Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Targeting Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.